International Oncology Network - Cancer & Hematology News
Peter Hofland, PhD's Blog – July 2012 Archive (4)
HPV Testing Can Predict Risk of Cervical Cancer for Up to 18 Years
A study published in the online edition of the July 30, 2012 issue of the Journal of Clinical Oncology (JCO) explores the long-term benefits of human papillomavirus (HPV) DNA testing alone, cytology (Pap testing), and combinations of the two, to predict cervical precancerous disease and invasive cervical cancer risk. Based on the outcome, the researchers concluded that primary…
ContinueAdded by Peter Hofland, PhD on July 30, 2012 at 9:30pm — No Comments
New U.S. Guideline Provides Offers Evidence-based Recommendations Sentinel Lymph Node Biopsy for Melanoma Staging
The American Society of Clinical Oncology (ASCO) and the Society for Surgical Oncology (SSO) earlier today jointly issued their first evidence-based clinical practice guideline on the use of sentinel lymph node biopsy or SLNB to stage patients with newly diagnosed melanoma.…
ContinueAdded by Peter Hofland, PhD on July 9, 2012 at 6:30pm — No Comments
First Patient Dosed in Phase Ib/IIa Study of CRLX101 in Combination with Bevacizumab in Renal Cancer
Earlier this week the first patient has been dosed in a Phase Ib/IIa study of CRLX101 (formerly called IT-101, Cerulean Pharma Inc.), dual inhibitor of topoisomerase 1 and hypoxia-inducible factor-1 alpha, in combination with bevacizumab (Avastin®, Genentech/Roche) in metastatic renal cell carcinoma (mRCC) patients. Cerulean also announced the completion of enrollment of its randomized Phase II study in advanced non-small…
ContinueAdded by Peter Hofland, PhD on July 2, 2012 at 7:00pm — No Comments
Head-to-Head Comparison Trial of Carfilzomib versus Bortezomib Starts Enrolling Patients with Relapsed Multiple Myeloma
Enrollment has started for the ENDEAVOR trial , a Phase III clinical trial evaluating carfilzomib (proposed brand name Kyprolis™, Onyx Pharmaceuticals, Inc) in combination with dexamethasone, versus bortezomib (originally codenamed PS-341 and marketed as Velcade® by Millennium Pharmaceuticals) with…
ContinueAdded by Peter Hofland, PhD on July 2, 2012 at 6:00pm — No Comments
Latest Blog Posts
- Enzastaurin Does Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma Study
- Study Evaluates Treatment of High Dose Aldesleukin + Vemurafenib in Patients with Metastatic Melanoma
- UK Charity Calls for More Attention and Awareness for Bladder Cancer
- Cryoablation Shows Promising Results in the Treatment of Breast Cancer
- Phase III Head-to-Head Study of Panitumumab Against Cetuximab in Metastatic Colorectal Cancer Meets Primary Endpoint of Non-Inferiority in Monotherapy Setting
- Phase II Monotherapy Study of Ibrutinib Shows CLL Patients Achieved Rapid and Sustainable Disease Control Irrespective of Age or High Risk Prognostic Factor
- Minimally Invasive, MRI-Guided Laser Treatment For Glioblastoma Found to be Safe in Phase I Trial
Most Popular Blog Posts
- Newly Identified microRNAs Could be Biomarkers for Early Diagnosis of Progression of Barrett's Esophagus and Esophageal Adenocarcinoma
- Scientific Advisory Board of Patient Advocate Organizations Disagree with Changes to Mammography Guidelines
- Updated Results for BTK Inhibitor Ibrutinib (PCI-32765) Shows Prolonged Progression Free Survival in High Risk, Advanced CLL/SLL and MCL Patients
- Deregulation of Several Genetic Pathways may Explain Treatment Resistance in Head and Neck Cancers
- Abiraterone Acetate Second-Line Treatment of Metastatic Castrate-Resistant Prostate Cancer (mCRPC) is Displacing Jevtana to Later-Line mCRPC
- Targeted Gold Nanoparticles and Noninvasive Radio Fields May Offer New Treatment Option for Pancreatic Carcinomas
- Phase I Clinical Trial Start for New Anti-Cancer Stem Cell Therapeutic OMP-59R5
Blog Topics by Tags
- cancer (555)
- Cancer (251)
- oncology (125)
- breast (100)
- treatment (93)
- ASCO (92)
- trial (78)
- Breast (75)
- FDA (69)
- chemotherapy (68)
- prostate (56)
- NSCLC (56)
- research (52)
- Oncology (50)
- tumor (49)
- risk (48)
- hematology (45)
- blood (45)
- screening (44)
- ESMO (44)
- cell (44)
- radiation (43)
- lung (42)
- Treatment (41)
- study (39)
- DNA (39)
- Leukemia (37)
- AACR (37)
- Patients (37)
- melanoma (36)
- therapy (36)
- diagnosis (35)
- prevention (34)
- Risk (32)
- Study (31)
- lymphoma (31)
- NCI (31)
- care (30)
- patients (30)
- inhibitor (29)
- Survival (29)
- disease (28)
- Roche (28)
- EGFR (27)
- protein (27)
- health (27)
- Metastatic (27)
- Prostate (27)
- Cell (26)
- Lung (26)
- leukemia (26)
- skin (26)
- women (25)
- Genentech (24)
- cells (24)
- carcinoma (24)
- colorectal (23)
- survival (23)
- gene (22)
- clinical (22)
- ASH (22)
- ovarian (22)
- kinase (22)
- Trial (21)
- pancreatic (21)
- metastatic (21)
- Europe (20)
- drug (20)
- Novartis (20)
- Research (20)
- Therapy (20)
- tumors (20)
- bevacizumab (19)
- KRAS (19)
- SABCS (18)
- Avastin (18)
- Advanced (18)
- Chemotherapy (18)
- AML (18)
- PSA (18)
- smoking (17)
- Women (17)
- pediatric (17)
- Pancreatic (17)
- Ovarian (16)
- pathway (16)
- Colorectal (16)
- TGen (16)
- brain (16)
- of (16)
- inhibitors (16)
- Pfizer (16)
- children (16)
- erlotinib (15)
- patient (15)
- ACS (15)
- CLL (15)
- ALL (15)
- Lymphoma (15)
- diagnostics (15)
Monthly Archives
2013
2012
- December (10)
- November (4)
- October (14)
- September (9)
- August (10)
- July (4)
- June (29)
- May (16)
- April (6)
- March (4)
- February (21)
- January (31)
2011
- December (44)
- November (32)
- October (21)
- September (32)
- August (18)
- July (23)
- June (81)
- May (45)
- April (54)
- March (36)
- February (61)
- January (43)
2010
- December (46)
- November (40)
- October (64)
- September (23)
- August (7)
- July (4)
- June (33)
- May (7)
- April (7)
- March (5)
- January (3)
2009
2008
- December (19)
2007
- April (1)
2005
2004
- September (1)
2001
- November (1)
ADVERTISEMENT
Bookmark / Share
Join the Conversation!
© 2013 Created by Peter Hofland, PhD.
